CD8 lymphocytes are sufficient for the development of chronic rejection

Transplantation

Volumn 78, Issue 11, 2004, Pages 1634-1639

  Schnickel, Gabriel T ^a,b   Whiting, David ^a   Hsieh, George R ^a,b   Yun, James J ^a   Fischbein, Michael P ^a   Fishbein, Michael C ^a   Yao, William ^a   Shfizadeh, Ali ^a   Ardehali, Abbas ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Gtr Los Angeles VA Hlthcare System   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

CD8 lymphocyte; Chronic rejection; Transplantation

Indexed keywords

ANTIBODY; CD40 ACTIVATING ANTIBODY; CD8 ANTIGEN; FAS LIGAND; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERFORIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CHRONIC GRAFT REJECTION; CYTOKINE PRODUCTION; DONOR; EFFECTOR CELL; FEMALE; HEART TRANSPLANTATION; HETEROTOPIC TRANSPLANTATION; HISTOCOMPATIBILITY TEST; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFER; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; SURGICAL TECHNIQUE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; FAS LIGAND PROTEIN; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; INTERFERON TYPE II; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; PORE FORMING CYTOTOXIC PROTEINS;

EID: 10644257283     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000141362.33931.40     Document Type: Article

References (34)

1. Weis M, von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 1997; 96: 2069.
2. Clarke-Forbes RD, Zheng SX, Gomersall M, et al. Evidence that recipient CD8+ T cell depletion does not alter development of chronic vascular rejection in a rate heart allograft model. Transplantation 1994; 57(8): 1238.
3. Shi C, Lee WS, He Q, et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci U S A 1996; 93(9): 4051.
4. Allan JS, Choo JK, Vesga L, et al. Cardiac allograft vasculopathy is abrogated by anti-CD8 monoclonal antibody therapy. Ann Thorac Surg 1997; 64(4): 1019.
5. Jones ND, Van Maurick A, Hara M, et al. CD40-CD40 Ligand-independent activation of CD8+ T cells can trigger allograft rejection. J Immunol 2000; 165: 1111.
6. Trambley J, Bingaman AW, Lin A, et al. Asialo GM1+ CD+ T cells play a critical role in costimulation blockade resistant allograft rejection. J Clin Invest 1999; 104: 1715.
7. Ensminger SM, Witzke O, Spriewald BM, et al. CD8+ T-cells contribute to the development of transplant arteriosclerosis despite CD154 blockade. Transplantation 2000; 69: 2609.
8. Fischbein MP, Yun J, Laks J, et al. CD8+ lymphocytes augment chronic rejection in a MHC class II mismatched model. Transplantation 2001; 71(8): 1146.
9. Fischbein MP, Yun J, Laks H, et al. Role of CD8 lymphocytes in chronic rejection of transplanted hearts. J Thorac Cardiovasc Surg 2002; 123: 803.
10. Delfs MW, Furukawa Y, Mitchell RN, et al. CD8+ T cell subsets TC1 and TC2 cause different histopathologic forms of murine cardiac allograft rejection. Transplantation 2001; 71: 606.
11. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell mediate cytotoxicity. Science 1994; 265: 528.
12. Sad S, Marcotte R, Mosmann TR. Cytokine induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 1995; 2: 271.
13. Nagano H, Mitchell R. Taylor M, et al. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 1998; 165(3): 550.
14. Kennedy JD, Pierce CW, Lake JP. Extrathymic T-cell maturation. J Immunol 1992; 148;6: 1620.
15. Corry R, Winn H, Russell P. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343.
16. Armstrong AT, Strauch AR, Starling RC, et al. Morphometric analysis of neointimal formation in murine cardiac grafts. Transplantation 1997; 63(8): 941.
17. Fischbein MP, Ardehali A, Yun J, et al. CD40 signalling replaces CD4+ lymphocytes and its blocking prevents chronic rejection of heart transplants. J Immunol 2000; 196(12): 7316.
18. Gilot BJ, Hara M, Jones ND, et al. Visualization of the in vivo generation of donor antigen-specific effector CD8+ T cells during mouse cardiac allograft rejection. Transplantation 2000; 69: 639.
19. Jones ND, van Maurik A, Hara M, et al. T-cell activation, proliferation, and memory after cardiac transplantation in vivo. Ann Surg 1999; 229: 570.
20. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480.
21. Kagi D, Odermatt B, Seiler RM, et al. Development of insulitis without diabetes in transgenic mice lacking perforin-dependent cytotoxicity. J Exp Med 1996; 183: 3143.
22. Kagi D, Odermatt B, Seiler P, et al. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med 1997; 183: 989.
23. Chervonsky AV, Wang Y, Wong FS, et al. The role of Fas in autoimmune diabetes. Cell 1997; 89: 17.
24. Amrani A, Verdaguer J, Anderson B, et al. Perforin-independent β-cell destruction by diabetogenic CD8+ T lymphocytes in transgenic nonobese diabetic mice. J Clin Invest 1999; 103: 1201.
25. Lu X, Ledermann B, Borel JF. Survival of islet grafts in perforin-deficient mice. Transplant Proc 1995; 27: 3262.
26. Hassan AT, Dai Z, Konieczny BT, et al. Acute rejection of vascularized heart allografts in the absence of IFN-γ:implications for long-term allograft acceptance. Transplantation 1999; 62: 1908.
27. Diamond AS, Gill RG. An essential contribution by IFN-γ to CD8+ T cell-mediated rejection of pancreatic islet allografts. J Immonol 2000; 165: 247.
28. Schultz M, Schuurman HJ, Jorgensen J, et al. Acute rejection of vascular heart allografts by perforin-deficient mice. Eur J Immunol 1995; 25: 474.
29. Seino K, Kayagaki N, Bashuda H, et al. Contribution of Fas ligand to cardiac allograft rejection. Int Immunol 1996; 8: 1347.
30. Boehm U, Klamp T, Groot M, et al. Cellular responses to interferon-γ. Annu Rev Immunol 1997; 15: 749.
31. Dellacasagrande J, Cap C, Raoult D, et al. IFN-γ-mediated control of Coxiella burnetii survival in monocytes: the role of cell apoptosis and TNF. J Immunol 1999; 162: 2259.
32. Loetscher M, Gerber B, Loetscher P, et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963.
33. Halloran P, Miller L, Urmson J, et al. IFN-γ alters the pathology of Graft protection: protection from early necrosis J Immunol 2001; 166(12): 7072.
34. Mele T, Kneteman N, Zhu L, et al. IFN-gamma is an absolute requirement for spontaneous acceptance of liver allografts. Am J Transplant 2003; 3(8): 942.